Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Lineage Cell Therapeutics reports 4th case of retinal tissue regeneration » 08:44
11/30/21
11/30
08:44
11/30/21
08:44
LCTX

Lineage Cell Therapeutics

$2.00 /

+0.01 (+0.50%)

Lineage Cell Therapeutics…

Lineage Cell Therapeutics announced that restoration of retinal tissue was observed in a fourth patient enrolled in the Company's Phase 1/2a clinical study of its lead product candidate, OpRegen. Retinal tissue restoration and improved visual acuity has now been observed in all four better vision patients treated in Cohort 4, where surgeons successfully covered the majority of the area of atrophy with a suspension of OpRegen cells. Outer retinal layer restoration, which was observed using clinical high-resolution Optical Coherence Tomography , was evidenced by the presence of new areas of retinal pigment epithelium monolayer with overlying ellipsoid zone, external limiting membrane, and outer nuclear layer, which were not present at the time of baseline assessment. These new and additive findings continue to support the Company's view that atrophic AMD is not an irreversible, degenerative condition and that some portion of diseased retinal tissue may be recoverable. OpRegen is an allogeneic RPE cell transplant in development for the treatment of age-related macular degeneration with geographic atrophy , or dry, or atrophic, AMD. "After reporting three previous cases of retinal restoration over the course of the last two years, we have been carefully examining the other Cohort 4 patients. We have put significant work into reviewing images from the remaining patient who had the majority of the area of atrophy covered by the OpRegen suspension at the time of surgical implant. I am pleased to report that at the scheduled Month 12 post-operative visit for this patient, although less prominent than the 3 previously reported cases due to a smaller area of atrophy at baseline, there is clear evidence of retinal restoration in some areas, and the total area of atrophy as calculated using square root transformation, or SQRT, is smaller than the size calculated at baseline," stated Jordi Mones, M.D., Ph.D., Director, Institut de la Macula and Director, Principal Investigator and Founder, Barcelona Macula Foundation. "The finding of a fourth case of restoration further supports our goal of showing that atrophic age-related macular degeneration can be responsive to this type of cell therapy. Dry AMD is a progressive disease and halting or reversing an area of atrophy does not occur spontaneously, which we believe makes the durability and reproducibility of these changes unprecedented within the field. With 12 months of follow-up complete, I am eager to have these cases submitted for peer-reviewed publication." "We have treated 24 patients with OpRegen, 12 of which were not legally blind at baseline and represent our intended treatment population. Among these 12 patients, four received thorough coverage of OpRegen cells across the majority of the atrophic area and experienced a cessation or reversal of their areas of atrophy at 12 months and continue to be followed. These patients also experienced increases in their visual acuity in their treated eye. We believe these four patients represent the only examples of an experimental treatment for dry AMD which can reduce an area of atrophy in humans, rather than simply slow its growth," added Brian M. Culley, Lineage CEO. "Restoration of retinal tissue using cell therapy represents a paradigm shift compared to conventional approaches, which to date have only shown an unremarkable slowing of progression. In addition to being well tolerated to date, the durability of changes to areas of atrophy and improvements in visual acuity support the continued and rapid clinical development of OpRegen. Alongside our advisors, we currently are preparing for multiple engagements with FDA to discuss aspects of OpRegen's designation, our manufacturing plans, and the design of a later-stage clinical trial to begin next year. We anticipate the first of these engagements will begin next month and continue in the first quarter of 2022."

ShowHide Related Items >><<
LCTX Lineage Cell Therapeutics
$2.00 /

+0.01 (+0.50%)

LCTX Lineage Cell Therapeutics
$2.00 /

+0.01 (+0.50%)

08/19/21 Noble Capital
Lineage Cell Therapeutics initiated with an Outperform at Noble Capital
03/30/21 Cantor Fitzgerald
Lineage Cell Therapeutics initiated with an Overweight at Cantor Fitzgerald
LCTX Lineage Cell Therapeutics
$2.00 /

+0.01 (+0.50%)

LCTX Lineage Cell Therapeutics
$2.00 /

+0.01 (+0.50%)

Earnings
Lineage Cell Therapeutics reports Q3 EPS (5c), consensus (5c) » 16:24
11/10/21
11/10
16:24
11/10/21
16:24
LCTX

Lineage Cell Therapeutics

$2.39 /

-0.095 (-3.83%)

Reports Q3 revenue $2.3M,…

Reports Q3 revenue $2.3M, consensus $0.5M. "Lineage's approach is to produce specific types of human cells and stably transplant those cells as a treatment for serious medical conditions. We believe our approach, in certain settings, can generate clinical outcomes beyond the reach of traditional methods, as evidenced by the restoration of retinal tissue in patients in our dry AMD trial and the restoration of a tissue matrix in patients in our spinal cord injury trial," stated Brian M. Culley, Lineage CEO. "During the third quarter, we reported positive interim outcomes in patients with dry AMD with geographic atrophy, initiated performance testing of our OPC1 delivery device for spinal cord injury, and we expanded our executive team with the appointment of a new General Counsel. Looking ahead, we are preparing for engagement with FDA for our OpRegen program to discuss aspects of product designation, manufacturing plans, and later-stage clinical development. In parallel, we look forward to the initiation of our OPC1 and novel delivery device clinical safety study early next year. We believe our technology platform has broad potential beyond even the indications we currently are pursuing and while we continue to advance our three clinical-stage programs, we also are evaluating new applications of our technology, either on our own or through strategic alliances."

ShowHide Related Items >><<
LCTX Lineage Cell Therapeutics
$2.39 /

-0.095 (-3.83%)

LCTX Lineage Cell Therapeutics
$2.39 /

-0.095 (-3.83%)

08/19/21 Noble Capital
Lineage Cell Therapeutics initiated with an Outperform at Noble Capital
03/30/21 Cantor Fitzgerald
Lineage Cell Therapeutics initiated with an Overweight at Cantor Fitzgerald
LCTX Lineage Cell Therapeutics
$2.39 /

-0.095 (-3.83%)

LCTX Lineage Cell Therapeutics
$2.39 /

-0.095 (-3.83%)

Over a month ago
Conference/Events
Lineage Cell Therapeutics management to meet virtually with B. Riley » 04:55
10/18/21
10/18
04:55
10/18/21
04:55
LCTX

Lineage Cell Therapeutics

$2.35 /

-0.035 (-1.47%)

Virtual Meeting to be…

Virtual Meeting to be held on October 18 hosted by B. Riley.

ShowHide Related Items >><<
LCTX Lineage Cell Therapeutics
$2.35 /

-0.035 (-1.47%)

LCTX Lineage Cell Therapeutics
$2.35 /

-0.035 (-1.47%)

08/19/21 Noble Capital
Lineage Cell Therapeutics initiated with an Outperform at Noble Capital
03/30/21 Cantor Fitzgerald
Lineage Cell Therapeutics initiated with an Overweight at Cantor Fitzgerald
LCTX Lineage Cell Therapeutics
$2.35 /

-0.035 (-1.47%)

LCTX Lineage Cell Therapeutics
$2.35 /

-0.035 (-1.47%)

Conference/Events
Lineage Cell Therapeutics management to meet virtually with B. Riley » 09:39
10/11/21
10/11
09:39
10/11/21
09:39
LCTX

Lineage Cell Therapeutics

$2.41 /

-0.04 (-1.63%)

Virtual Meeting to be…

Virtual Meeting to be held on October 18 hosted by B. Riley.

ShowHide Related Items >><<
LCTX Lineage Cell Therapeutics
$2.41 /

-0.04 (-1.63%)

LCTX Lineage Cell Therapeutics
$2.41 /

-0.04 (-1.63%)

08/19/21 Noble Capital
Lineage Cell Therapeutics initiated with an Outperform at Noble Capital
03/30/21 Cantor Fitzgerald
Lineage Cell Therapeutics initiated with an Overweight at Cantor Fitzgerald
LCTX Lineage Cell Therapeutics
$2.41 /

-0.04 (-1.63%)

LCTX Lineage Cell Therapeutics
$2.41 /

-0.04 (-1.63%)

Conference/Events
Lineage Cell Therapeutics management to meet with  12:35
10/08/21
10/08
12:35
10/08/21
12:35
LCTX

Lineage Cell Therapeutics

$2.44 /

-0.01 (-0.41%)

Meeting to be held

ShowHide Related Items >><<
LCTX Lineage Cell Therapeutics
$2.44 /

-0.01 (-0.41%)

LCTX Lineage Cell Therapeutics
$2.44 /

-0.01 (-0.41%)

08/19/21 Noble Capital
Lineage Cell Therapeutics initiated with an Outperform at Noble Capital
03/30/21 Cantor Fitzgerald
Lineage Cell Therapeutics initiated with an Overweight at Cantor Fitzgerald
LCTX Lineage Cell Therapeutics
$2.44 /

-0.01 (-0.41%)

LCTX Lineage Cell Therapeutics
$2.44 /

-0.01 (-0.41%)

Conference/Events
The Retina Society to hold annual scientific meeting » 04:55
10/02/21
10/02
04:55
10/02/21
04:55
APLS

Apellis

$33.60 /

+0.64 (+1.94%)

, RGNX

Regenxbio

$40.22 /

-1.78 (-4.24%)

, CHRS

Coherus Biosciences

$16.50 /

+0.43 (+2.68%)

, LCTX

Lineage Cell Therapeutics

$2.58 /

+0.05 (+1.98%)

54th Annual Scientific…

54th Annual Scientific Meeting to be held in Chicago on September 29-October 2.

ShowHide Related Items >><<
RGNX Regenxbio
$40.22 /

-1.78 (-4.24%)

LCTX Lineage Cell Therapeutics
$2.58 /

+0.05 (+1.98%)

CHRS Coherus Biosciences
$16.50 /

+0.43 (+2.68%)

APLS Apellis
$33.60 /

+0.64 (+1.94%)

APLS Apellis
$33.60 /

+0.64 (+1.94%)

10/01/21 Jefferies
Apellis' pecetacoplan has approvable profile in GA, says Jefferies
10/01/21 Cantor Fitzgerald
Cantor sees 'high likelihood' of approval for Apellis in geographic atrophy
09/16/21 BMO Capital
NGM Biopharmaceuticals price target raised to $35 from $29 at BMO Capital
09/13/21 Baird
Apellis price target lowered to $75 from $80 at Baird
RGNX Regenxbio
$40.22 /

-1.78 (-4.24%)

09/14/21 Barclays
Regenxbio price target raised to $82 from $79 at Barclays
09/13/21 Chardan
Regenxbio pact with AbbVie accelerates RGX-314 'value capture,' says Chardan
07/09/21 Chardan
Regenxbio coverage transferred at Chardan
04/29/21 Chardan
Chardan downgrades Adverum after serious adverse reaction disclosure
CHRS Coherus Biosciences
$16.50 /

+0.43 (+2.68%)

07/23/21 H.C. Wainwright
Coherus Biosciences price target raised to $36 from $26 at H.C. Wainwright
05/17/21 Barclays
Coherus Biosciences price target lowered to $24 from $28 at Barclays
05/07/21 H.C. Wainwright
Coherus Biosciences price target lowered to $26 from $28 at H.C. Wainwright
02/25/21 Citi
Coherus Biosciences price target lowered to $27 from $30 at Citi
LCTX Lineage Cell Therapeutics
$2.58 /

+0.05 (+1.98%)

08/19/21 Noble Capital
Lineage Cell Therapeutics initiated with an Outperform at Noble Capital
03/30/21 Cantor Fitzgerald
Lineage Cell Therapeutics initiated with an Overweight at Cantor Fitzgerald
RGNX Regenxbio
$40.22 /

-1.78 (-4.24%)

LCTX Lineage Cell Therapeutics
$2.58 /

+0.05 (+1.98%)

CHRS Coherus Biosciences
$16.50 /

+0.43 (+2.68%)

APLS Apellis
$33.60 /

+0.64 (+1.94%)

  • 08
    Jan
LCTX Lineage Cell Therapeutics
$2.58 /

+0.05 (+1.98%)

APLS Apellis
$33.60 /

+0.64 (+1.94%)

APLS Apellis
$33.60 /

+0.64 (+1.94%)

Conference/Events
The Retina Society to hold annual scientific meeting » 04:55
10/01/21
10/01
04:55
10/01/21
04:55
APLS

Apellis

$32.97 /

-0.995 (-2.93%)

, RGNX

Regenxbio

$41.94 /

-0.15 (-0.36%)

, CHRS

Coherus Biosciences

$16.07 /

-0.39 (-2.37%)

, LCTX

Lineage Cell Therapeutics

$2.53 /

-0.02 (-0.78%)

54th Annual Scientific…

54th Annual Scientific Meeting to be held in Chicago on September 29-October 2.

ShowHide Related Items >><<
RGNX Regenxbio
$41.94 /

-0.15 (-0.36%)

LCTX Lineage Cell Therapeutics
$2.53 /

-0.02 (-0.78%)

CHRS Coherus Biosciences
$16.07 /

-0.39 (-2.37%)

APLS Apellis
$32.97 /

-0.995 (-2.93%)

APLS Apellis
$32.97 /

-0.995 (-2.93%)

09/16/21 BMO Capital
NGM Biopharmaceuticals price target raised to $35 from $29 at BMO Capital
09/13/21 Baird
Apellis price target lowered to $75 from $80 at Baird
09/12/21 Raymond James
NGM Biopharmaceuticals upgraded to Strong Buy from Outperform at Raymond James
09/10/21 BMO Capital
Apellis price target lowered to $69 from $89 at BMO Capital
RGNX Regenxbio
$41.94 /

-0.15 (-0.36%)

09/14/21 Barclays
Regenxbio price target raised to $82 from $79 at Barclays
09/13/21 Chardan
Regenxbio pact with AbbVie accelerates RGX-314 'value capture,' says Chardan
07/09/21 Chardan
Regenxbio coverage transferred at Chardan
04/29/21 Chardan
Chardan downgrades Adverum after serious adverse reaction disclosure
CHRS Coherus Biosciences
$16.07 /

-0.39 (-2.37%)

07/23/21 H.C. Wainwright
Coherus Biosciences price target raised to $36 from $26 at H.C. Wainwright
05/17/21 Barclays
Coherus Biosciences price target lowered to $24 from $28 at Barclays
05/07/21 H.C. Wainwright
Coherus Biosciences price target lowered to $26 from $28 at H.C. Wainwright
02/25/21 Citi
Coherus Biosciences price target lowered to $27 from $30 at Citi
LCTX Lineage Cell Therapeutics
$2.53 /

-0.02 (-0.78%)

08/19/21 Noble Capital
Lineage Cell Therapeutics initiated with an Outperform at Noble Capital
03/30/21 Cantor Fitzgerald
Lineage Cell Therapeutics initiated with an Overweight at Cantor Fitzgerald
RGNX Regenxbio
$41.94 /

-0.15 (-0.36%)

LCTX Lineage Cell Therapeutics
$2.53 /

-0.02 (-0.78%)

CHRS Coherus Biosciences
$16.07 /

-0.39 (-2.37%)

APLS Apellis
$32.97 /

-0.995 (-2.93%)

  • 08
    Jan
LCTX Lineage Cell Therapeutics
$2.53 /

-0.02 (-0.78%)

APLS Apellis
$32.97 /

-0.995 (-2.93%)

APLS Apellis
$32.97 /

-0.995 (-2.93%)

Conference/Events
The Retina Society to hold annual scientific meeting » 09:23
09/30/21
09/30
09:23
09/30/21
09:23
APLS

Apellis

$33.97 /

-1.245 (-3.54%)

, RGNX

Regenxbio

$42.13 /

-1.35 (-3.10%)

, CHRS

Coherus Biosciences

$16.47 /

-0.46 (-2.72%)

, LCTX

Lineage Cell Therapeutics

$2.55 /

+0.06 (+2.41%)

54th Annual Scientific…

54th Annual Scientific Meeting to be held in Chicago on September 29-October 2.

ShowHide Related Items >><<
RGNX Regenxbio
$42.13 /

-1.35 (-3.10%)

LCTX Lineage Cell Therapeutics
$2.55 /

+0.06 (+2.41%)

CHRS Coherus Biosciences
$16.47 /

-0.46 (-2.72%)

APLS Apellis
$33.97 /

-1.245 (-3.54%)

APLS Apellis
$33.97 /

-1.245 (-3.54%)

09/16/21 BMO Capital
NGM Biopharmaceuticals price target raised to $35 from $29 at BMO Capital
09/13/21 Baird
Apellis price target lowered to $75 from $80 at Baird
09/12/21 Raymond James
NGM Biopharmaceuticals upgraded to Strong Buy from Outperform at Raymond James
09/10/21 BMO Capital
Apellis price target lowered to $69 from $89 at BMO Capital
RGNX Regenxbio
$42.13 /

-1.35 (-3.10%)

09/14/21 Barclays
Regenxbio price target raised to $82 from $79 at Barclays
09/13/21 Chardan
Regenxbio pact with AbbVie accelerates RGX-314 'value capture,' says Chardan
07/09/21 Chardan
Regenxbio coverage transferred at Chardan
04/29/21 Chardan
Chardan downgrades Adverum after serious adverse reaction disclosure
CHRS Coherus Biosciences
$16.47 /

-0.46 (-2.72%)

07/23/21 H.C. Wainwright
Coherus Biosciences price target raised to $36 from $26 at H.C. Wainwright
05/17/21 Barclays
Coherus Biosciences price target lowered to $24 from $28 at Barclays
05/07/21 H.C. Wainwright
Coherus Biosciences price target lowered to $26 from $28 at H.C. Wainwright
02/25/21 Citi
Coherus Biosciences price target lowered to $27 from $30 at Citi
LCTX Lineage Cell Therapeutics
$2.55 /

+0.06 (+2.41%)

08/19/21 Noble Capital
Lineage Cell Therapeutics initiated with an Outperform at Noble Capital
03/30/21 Cantor Fitzgerald
Lineage Cell Therapeutics initiated with an Overweight at Cantor Fitzgerald
RGNX Regenxbio
$42.13 /

-1.35 (-3.10%)

LCTX Lineage Cell Therapeutics
$2.55 /

+0.06 (+2.41%)

CHRS Coherus Biosciences
$16.47 /

-0.46 (-2.72%)

APLS Apellis
$33.97 /

-1.245 (-3.54%)

  • 08
    Jan
LCTX Lineage Cell Therapeutics
$2.55 /

+0.06 (+2.41%)

APLS Apellis
$33.97 /

-1.245 (-3.54%)

APLS Apellis
$33.97 /

-1.245 (-3.54%)

Over a quarter ago
Hot Stocks
Lineage Cell Therapeutics appoints George Samuel III as general counsel » 08:11
09/01/21
09/01
08:11
09/01/21
08:11
LCTX

Lineage Cell Therapeutics

$2.52 /

+0.06 (+2.44%)

Lineage Cell Therapeutics…

Lineage Cell Therapeutics announced that it has appointed George Samuel III as Lineage's general counsel and corporate secretary. Samuel will lead the company's legal operations, bringing extensive corporate, transactional, intellectual property and commercial expertise which spans nearly 15 years across the life sciences and technology sectors as well as in private practice. Prior to joining Lineage, Samuel most recently served as director, senior counsel for Lytx, where he managed the commercial legal operations for an international video telematics SaaS company.

ShowHide Related Items >><<
LCTX Lineage Cell Therapeutics
$2.52 /

+0.06 (+2.44%)

LCTX Lineage Cell Therapeutics
$2.52 /

+0.06 (+2.44%)

08/19/21 Noble Capital
Lineage Cell Therapeutics initiated with an Outperform at Noble Capital
03/30/21 Cantor Fitzgerald
Lineage Cell Therapeutics initiated with an Overweight at Cantor Fitzgerald
09/17/20 Noble Capital
Lineage Cell Therapeutics initiated with an Outperform at Noble Capital
LCTX Lineage Cell Therapeutics
$2.52 /

+0.06 (+2.44%)

LCTX Lineage Cell Therapeutics
$2.52 /

+0.06 (+2.44%)

Initiation
Lineage Cell Therapeutics initiated with an Outperform at Noble Capital » 08:30
08/19/21
08/19
08:30
08/19/21
08:30
LCTX

Lineage Cell Therapeutics

$2.42 /

-0.02 (-0.82%)

Noble Capital analyst…

Noble Capital analyst Robert LeBoyer initiated coverage of Lineage Cell Therapeutics with an Outperform rating and $8 price target. Lineage's lead product OpRegen is in development for dry age-related macular degeneration, or dry AMD, with its next clinical trial planned in late 2021 to early 2022, noted LeBoyer.

ShowHide Related Items >><<
LCTX Lineage Cell Therapeutics
$2.42 /

-0.02 (-0.82%)

LCTX Lineage Cell Therapeutics
$2.42 /

-0.02 (-0.82%)

03/30/21 Cantor Fitzgerald
Lineage Cell Therapeutics initiated with an Overweight at Cantor Fitzgerald
09/17/20 Noble Capital
Lineage Cell Therapeutics initiated with an Outperform at Noble Capital
08/31/20 H.C. Wainwright
Lineage Cell extends cash runway to over two years, says H.C. Wainwright
LCTX Lineage Cell Therapeutics
$2.42 /

-0.02 (-0.82%)

LCTX Lineage Cell Therapeutics
$2.42 /

-0.02 (-0.82%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.